48 results about "Blood group antibodies" patented technology

The present invention discloses a blood type detection method based on a membrane structure. According to the method, a filtration membrane allowing a single red blood cell to pass through is selected as a core material, blood type antibodies are bound to the filtration membrane, a water absorption material is surrounding the periphery of the filtration membrane, red blood cells with a certain concentration are added on the filtration membrane surface in a dropwise manner during detecting, rinsing is performed with a rinsing liquid, the red blood cells with no antigen-antibody binding exude along with the rinsing liquid, the red blood cells with the antigen-antibody binding are remained on the membrane surface so as to form the visible red clumps, and an operator can judge the result according to whether the red blood cells form the visible red clumps on the filtration membrane so as to determine the blood type of red blood cells. The method of the present invention has beneficial effects of short detection time and objective result.

The invention relates to a detection plate and identification method based on solid-phase method for rapid blood type identification. The detection plate includes a plate body, a sample tank arranged in the middle of the plate body, an antibody tank set on one side of the sample tank, and an antibody tank set on the other side of the sample tank. The gold-labeled tank on the side has monoclonal antibody in the antibody tank, and the gold-labeled red blood cell membrane antigen is arranged in the gold-labeled tank, and upper absorbent paper is arranged between the sample tank and the antibody tank, and between the sample tank and the gold-labeled tank A blood filter membrane is arranged between them, and a lower absorbent paper is arranged below the blood filter membrane; the present invention adopts specific monoclonal anti-A, anti-B, and anti-D antibodies as ABO blood type positive typing reagents, and adopts marker specificity Erythrocyte membrane A, B, O blood group antigens (gold standard antigens) are used as anti-stereotyping immune colloidal gold reagents. Both the positive and negative stereotyping reagents are set on the plate body, which is simple and quick to operate, easy to carry, and high in accuracy. It is suitable for mobile blood collection points and The blood typing reagent for emergency blood transfusion is placed in the popping beads at the same time, the positive and negative typing reagents.

The invention relates to an immunochromatographic test strip for determining IgG anti-A and anti-B blood group antibodies of a pregnant woman or human blood-group reverse typing, and belongs to the technical field of biological medicines. The immunochromatographic test strip comprises a sample pad, a tracing pad, a cellulose membrane, an IgM blocking area, an IgG detecting area, a quality control area, a water absorbing pad and a supporting plate, wherein the supporting plate is positioned at the bottom part and is provided with the cellulose membrane, and the two ends of the cellulose membrane are respectively overlapped with the tracing pad and the water absorbing pad; and the sample pad is overlapped on the other end of the tracing pad. The immunochromatographic test strip has the advantages that the existence and the titer of human blood IgG-type anti-A and anti-B antibodies can be simply and rapidly determined in a specific manner, the traditional and current determination mode 'IgM inactivation, anti-human ball test and agglutination observation 'is replaced, the operation steps are greatly simplified, and the time consumed is shortened; and the immunochromatographic test strip also can be used for determining the reverse typing of human blood.

The invention discloses a Miltenberger blood group antibody detection immunofluorescent chromatography test strip and a detection method thereof. The Miltenberger blood group antibody detection immunofluorescent chromatography test strip comprises a sample pad, a reaction film and an absorption pad which are in an ordinal overlap joint relationship. Two ends of the sample pad are provided with a first sample injection point and a second sample injection point. An inner quality control band and at least one antibody detection band are fixed to the reaction film. The detection method comprises the following steps of mixing a biotin-labelled polypeptide blood group antigen and a serum sample, adding the mixture into the sample pad, adding a fluorescent label second antibody into the sample pad, and carrying out detection by a fluorescence detector. The Miltenberger blood group antibody detection immunofluorescent chromatography test strip solves the problem that a simple and practical clinical conventional Miltenberger blood group antibody detection technology and a reagent are deficient, is used for assistant clinical diagnosis of Miltenberger blood group antibody-caused hemolytic disease of the newborn, and adverse effects of blood transfusion, and guarantees clinical safety, effectiveness and scientific blood transfusion.

The invention relates to an automatic detection card and detection method of a multi-blood group system. The automatic detection card comprises four parts, namely a sample addition layer, a reaction layer, a developing layer and an identification layer from top to bottom, wherein a sample addition hole is formed in the sample addition layer, a full-blood pad or a filter pad for filtering red bloodcells from full blood is arranged on the reaction layer, the bottom of the sample addition hole is connected with the full-blood pad or the filter pad, a tail end of the full-blood pad is connected with a plurality of antibody pads pre-coated with blood group antibodies, a tail end of the filter pad is connected with an antigen pad, pre-coated with a blood group antigen, through a delay pad, thereaction layer is separately provided with a quality control strip, a plurality of developing regions connected with tail end(s) of the antibody pads or the antigen pad are arranged on the developinglayer, and the identification layer is reversely connected with the developing layer. In the automatic detection card, blood group detection and a coding technology are combined, multiple blood groupscan be rapidly detected, automatic identification of multiple blood groups is achieved, artificial judgment errors are reduced, the detection efficiency is improved, special equipment is not needed,and rapid, accurate, automatic and portable detection of the blood groups is achieved.

The invention relates to a therapeutic apparatus for treating a maternal-fetal blood group incompatibility-type hemolytic disease in the medical field. The therapeutic apparatus is characterized in that hemoglobin with toxic and side effects is removed from Rh-positive red blood cells through diapedesis by using PB lysate, but ghost cells which only absorb an Rh antibody and do not absorb other blood group antibodies are retained; together with an immunologically prepared anti-Rh antibody, the ghost cells are fixed to agarose with a special concentration according to a specific ratio; thereafter, the agarose is enwrapped by a cylindrical container made of a highly-biocompatible material so as to form gradually decreasing antibody valence, gradually increasing agarose concentration and uniform ghost cell distribution from a sample inlet end to a sample outlet end; near the sample outlet end, the agarose with the special concentration with gradually increasing concentration and gradually diminishing micropores can effectively intercept fragments formed after the red blood cells of a patient suffering from the hemolytic disease are destroyed, as well as macromolecular immune complexes combined with the fragments. The therapeutic apparatus provides a new toxic and side effect-free method for treating the maternal-fetal blood group incompatibility-type hemolytic disease, by which only pathogenic antibodies are removed, but plasma components are not removed.

The invention provides superparamagnetism functional particles and magnetized red blood cells. The surfaces of bacterial magnetic particles naturally carry rich -NH2 groups, the bacterial magnetic particles are modified through a certain chemical method so as to be activated and are in coupling connection with an anti-red blood cell GP (Glycoprotein) A monoclonal antibody, so that the superparamagnetism functional particles are prepared; before clinical blood group antibody detection, the superparamagnetism functional particles can be in incubation with red blood cells and can be quickly magnetized, then sample detection can be carried out, and centrifugal separation is replaced with magnetic separation during a detection process. A quick, simple and convenient testing method is provided for clinical application, and the superparamagnetism functional particles provided by the invention are especially beneficial for quick magnetization of the red blood cells and solid-liquid separation during a clinical blood group antibody detection process.

A maternal-fetal blood group incompatibility immunosorbent therapy apparatus used in the medical field is characterized in that a blood separator and a plasma adsorber are connected through a circulation line to form a cardiopulmonary bypass adsorption device, wherein the blood separator is used for separating blood cells and plasma, as the separated plasma flows through and filters through the plasma adsorber, wherein the pathogenic antibody is adsorbed, the filtered plasma is combined with the separated blood cells and then re-enters a cardiopulmonary bypass adsorption device for circulatingadsorption to achieve the purpose of cleaning the pathogenic antibody, and the plasma adsorber is filled with a solid-phase carrier coated with blood group antigen or anti-blood group antibody with high to low gradient titer from an inlet to an outlet in a layered manner.

The invention relates to a method and a system for detecting an Rh blood group antigen and application thereof, and belongs to the technical field of biological detection. The invention provides a positive typing method for detecting an Rh blood group antigen based on solid phase adsorption, which comprises the following steps: adding red blood cells to be typed and an Rh blood group antibody into a container coated with second antibodies of other species, performing centrifuging, and observing whether the red blood cells to be typed are adsorbed at the bottom of the container coated with the second antibodies of other species; if the red blood cells to be typed are adsorbed at the bottom of the container coated with the second antibodies of other species, determining that the red blood cells to be typed and Rh blood group antigens corresponding to the Rh blood group antibodies are positive, and if the red blood cells to be typed are not adsorbed at the bottom of the container coated with the second antibodies of other species, determining that the red blood cells to be typed and Rh blood group antigens corresponding to the Rh blood group antibodies are negative. The method is high in sensitivity, strong in specificity and low in detection cost, has the advantage of easiness in automatic operation, and can avoid personal errors in the operation process.

The present invention provides novel methods for the detection of antibodies, in particular, blood group antibodies. The methods of this invention may be applied to pre-transfusion blood compatibility testing for the detection of incompatibility between donor units (comprising donor red blood cells (erythrocytes)) and a recipient.

The present invention provides a blood group antibody complex whose structure is blood group antibody I-bridged secondary antibody-blood group antibody II. The present invention also provides a method for preparing the above-mentioned blood group antibody complex, comprising the following steps: S1, selecting two antibodies derived from the same biological species, namely blood group antibody I and blood group antibody II; S2, according to the blood group antibody Species sources of I and blood group antibody II, select a bridged secondary antibody that can specifically bind to blood group I and blood group antibody II at the same time; Mix evenly at a ratio of 1:1:1, and place at room temperature for 15-30 minutes to prepare a complex with the structure of blood group antibody I-bridged secondary antibody-blood group antibody II. The preparation method of the blood group antibody complex provided by the present invention can increase the specificity of the blood group antibody or improve the affinity and titer of the blood group antibody by utilizing the specific recognition between the antibody and its specific antibody, and the operation is simple and fast. Wide range of applications.

The invention discloses a rapid detection kit for IgG blood group antibody titer. The rapid detection kit comprises a standard red blood cell suspension, a flushing fluid and a detection test strip; the detection test strip comprises a sample adding part, a reaction part and a water absorption part which are sequentially arranged in a contact manner from the upstream side to the downstream side; the sample adding part is sequentially provided with a washing sample adding area, an erythrocyte sample adding area and a sample adding area from the upstream side to the downstream side; the reactionpart is provided with at least one detection point and a contrast point, wherein at least one detection point is coated and cured with an anti-human IgG antibody, and the contrast point is coated andcured with an anti-RBC antibody. When the kit is used, only one-step sample adding, red blood cell adding and flushing fluid adding are needed, and a result can be obtained after 3-5 minutes.

The invention provides a novel immune medicine for treating solid tumors, the immune medicine comprises a virus expression vector for simultaneously expressing a Fut1 gene and an ABO blood group gene,and the ABO blood group gene comprises an N-acetylgalactosamine transferase gene and/or a galactosyl transferase gene. According to the immune drug, a human ABO blood group gene is cloned to a medical drug-grade lentiviral vector; co-expression with a Fut1 gene is carried out; the prepared medical drug-grade lentiviral drug is injected into a tumor part through a solid tumor local injection method; according to the present invention, the target gene sequence is permanently translated in tumor cells, such that a large amount of the blood group antigen is expressed on the surface of the tumor cell membrane, and the blood group antigen can be recognized by the corresponding blood group antibody existing in serum so as to activate the complement so as to kill the tumor cells and achieve the tumor reduction purpose;